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Summary: To evaluate the role of serotonin in liver cirrhosis, serotonin was determined by high-performance
liquid chromatography in plasma, platelets and ascitic fluids from 14 cirrhotic patients. Plasma-free serotonin
was within the normal ränge, but intraplatelet serotonin was significantly low in cirrhosis (p < 0.001) and
this decrease paralleled the severity of the disease. The concentration of serotonin in ascitic fluids was 12%
of the corresponding plasma concentrations.
Our data indicate that serotonin levels are influenced by hepatic injury, but the reasons for these changes are
still unclear.
Introduction
The hypersensitivity to serotonin of isolated mesen-
teric veins from portal hypertensive rats (1) and the
beneficial haemodynamic effects of ketanserin, a se-
lective inhibitor of serotonin2-receptors, in portal hy-
pertensive animals and in patients with liver cirrhosis
(2) prompted us to measure the concentrations of
serotonin in plasma, platelets and ascitic fluid from
cirrhotic patients, to determine whether serotonin
might be involved in liver cirrhosis.
Experimental
Fourteen patients, with diagnoses of liver cirrhosis (8 alcoholic
and 6 postnecrotic, mean age ± S.O.: 61 ± 11 years) based on
liver biopsy and/or on typical physical and laböratory fmdings,
were studied.
Drugs affecting platelets and serotonin were discontinued at
least 8 days prior to blood sampling. Thirteen healthy volun-
teers matched for age and sex sefved äs normal controls.
Plasma and platelet serotonin was measured by high-perform-
ance liquid chromatography using an electrochemical detector.
Venous blood obtained without stasis was collected in 10 ml
tubes containing 3 mmol/1 sodiurn EDTA, 50 nmol/1 pargyline,
l mmol/1 theophylline, 5 nmol/1 imipramine and 33 nmol/1 pros-
taglandin Ej.
Platelet-rich plasma obtained by low speed centrifugation
(130 g, 10 min) was diluted with platelet-poor plasma, obtained
by higher speed centrifugation (950 g, 10 min) to yield platelet
samples containing 110 ±20 · 109/1- Intraplatelet or plasma
serotonin was extracted following the method of Picard et al.
(3). Briefly, to 0.1 ml of platelet-rich plasma (subjected to
ultrasonic treatment for 20 s), or to l ml of platelet-poor
plasma, were added a fixed amount of internal Standard (5-
hydroxy-N^methyltryptamine), l ml of buffer (pH 11, contain-
ing glydne, 0.1 mol/1 NaOH and 0.1 mol/1 NaCl) and 5 ml of
chlorofonn/1-pentanol (60 4- 20, by vol., saturated with water).
Samples were shaken for 10 min and centrifuged (2000g, 10
min). The organic phase was transferred to a second vial con-
taining 400 ul 0.1 mol/1 HC1, shaken for 10 min and centrifuged
(2000g, 10 min). The aqueous phase was injected into the
Chromatograph.
The high-performance liquid Chromatographie System consisted
öf a Perkin Eimer Series 2 pump (Perkin-Elmer, Norwalk, CT,
U. S. A.), with a Model 7125 Rheodyne valve (Rheodyne,
Berkely, CA, U. S. A.); a Nucleosil C18 column (5 ; 150
6 mm inside diameter), (Alltech Europe, Nazareth, Belgium);
a Model 5100 A Coulochem detector (ESA Inc., Bedford, MA,
U. S. A.) and a Model 561 Hitachi Recorder (Tokyo, Japan).
The mobile phase (l ml/min, room temperature) consisted of
0.05 mol/1 acetate-citrate buffer (pH 4.6) containing 50 ml/l
methanol. The average coefficient of Variation of the method
and the lowest limit of detection have been shown to be 3.5%
and 1.2 nmol/1, respectively (4).
Ascites drawn from five patients was processed äs described
for blood and assayed for serotonin.
Serotonin levels in patients and controls were compared with
the aid of a paired Student t-test. Statistical differences between
patient groups were established by use of one way variance
analysis and the Scheffe multiple comparison test. Differences
were considered significant when the two-tailed p was less than
0.01.
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Results
Platelets from cirrhotic patients contained signifi-
cantly less serotonin than those from normal controls
(p < 0.001), while the levels of free circulating sero-
tonin in the two groups were similar (tab. 1). We
found no significant correlation between circulating
and intraplatelet serotonin levels in patients or in
controls, and none of the serotonin measurements
correlated with the platelet count, serum albumin,
ammonia, transaminase, immunoglobulins and cre-
atinine, or the presence of cholostasis. However, pa-
tients with more severe disease — severity was graded
by the Child criteria (5) — had significantly lower
intraplatelet serotonin than patients with milder dis-
ease (p < 0.01). There were no significant differences
in circulating serotonin (fig. 1). Neither circulating
serotonin (18.2 ± 15.8 vs 22.1 ± 20.4 ntnol/1, mean
+ S. D.) nor platelet serotonin (2.5 + 0.8 vs 2.6 ± 2.2
nmol/109 platelets) could distinguish alcoholic from
postnecrotic cirrhosis. All the ascitic fluids had ap-
preciable amounts of serotonin, representing 12% of
the corresponding plasma values (tab. 1). One value,
from a haemorrhagic fluid, was 140% of the corre-
sponding plasma level (17.0 and 12.5 nmol/1, ascites
and plasma), and this was not included in the calcu-
lations of table l.
Tab. 1. Concentrations (mean ± S. D.) of serotonin in plasma,
platelets and ascites from cirrhotic patients and healthy
controls.
Cirrhotics
Controls
Plasma
(nmol/1)
19.9 ± 17.0
15.0 ± 6.2
Platelets
(nmol/109 platelets)
2.5 ± 1.6(*)
4.6 ± 1.2
Ascites
(nmol/1)
3.4 ± 1.7
(*) p < 0.001 (patients vs controls)
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Fig. 1. Circulating (plasma, a) and intraplatelet (b) serotonin
levels (mean ± S. D.) from cirrhotic patients grouped
,upon the Child-Turcotte criteria A, B, C.
A indicates the mildest hepatic injury and C the most
severe.
The differences in plasma values are not significant. For
intraplatelet values A vs. C is significant at p < 0.01.
The concentration of serotonin in ascites was inde-
pendent of the plasma and intraplatelet serotonin
contents and of the levels of proteins, glucose, alkaline
phosphatase, amylase or urea in the ascitic fluid.
Discussion
• r
Until now, no data haVe been published on plasma
free serotonin in liver diseases. Low intraplatelet ser-
otonin was previously observed by Ahtee et al. in a
small number of patients with alcoholic liver cirrhosis,
and considered to be due to reduced platelet serotonin
uptake (6, 7). However, reduced uptake should lead
to increased concentrations of free serotonin in
plasma, but free serotonin was found to be within the
normal ränge in the plasma of our patients. However,
a number of factors might influence the concentration
of circulating serotonin in cirrhotics, e. g. the by^pass
of portal blood in systemic circulatioü, an altered
serotonin catabolism due to increased monoaminox-
idase activity (8), an abnormal ävailäbility of free
tryptophan, the precursor of serotonin (9). The wide
ränge of circulating serotonin found in cirrhotics
might well be the result of a large number pf different
contributing factors. Free serotonin levels are thus
not representative of the extent of hepatic injury. The
low intraplatelet serotonin and, more significantly,
the fact that platelet serotonin decreased äs the se-
verity of liver disease increased, are difficult to ex-
plain. It has been reported that platelet uptake of
serotonin is reduced in liver cirrhosis (6, 7), büt the
mechanism for this is not known, even though met-
abolic factors or altered serotonin receptors can be
hypothesized (7).
The normal concentration of free serotonin (free ser-
otonin is the active form of serotonin) found in cir-
rhotic plasma does not indicate a role for ketanserin
in liver cirrhosis. On the other band, the observation
that platelets containing low serotonin are more re-
sponsive to serotonin-induced aggregation iii vitro
(10) and the abnormal vascular sensitivity to serotonin
of mesenteric veins from portal hypertensive rats (1)
might indicate a role for such serotonin2 receptpr
antagonists in liver disorders.
In conclusion, our data indicate that:
1) intraplatelet serotonin levels are influenced by he-
patic cirrhosis and
2) intraplatelet but not circulating serotonin is an
index of the severity of hepatic dainage.
The factors underlying this observation, and the ques-
tion of whether it can be influenced by ketanserin
require further study.
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